Pharmanutra SpA (PHN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.17 k

Shareholding (Dec 2023)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

ROCE(HY) Lowest at 0%
INTEREST COVERAGE RATIO(Q) Lowest at 3,974.04
INVENTORY TURNOVER RATIO(HY) Lowest at 0%

With ROE of 26.95%, it has a Very Expensive valuation with a 7.51 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 523 Million ()

P/E

28.00

Industry P/E

Dividend Yield

0.02%

Debt Equity

0.18

Return on Equity

25.79%

Price to Book

7.91

Revenue and Profits:

Net Sales:

26 Million

(Quarterly Results - Mar 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

25.44%

6 Months

7.29%

1 Year

-1.3%

2 Years

-4.33%

3 Years

-15.34%

4 Years

-27.4%

5 Years

57.27%

Pharmanutra SpA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.11%

EBIT Growth (5y)

14.84%

EBIT to Interest (avg)

17.12

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.12

Sales to Capital Employed (avg)

1.21

Tax Ratio

39.63%

Dividend Payout Ratio

57.85%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

62.00%

ROE (avg)

28.41%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.51

EV to EBIT

17.33

EV to EBITDA

15.39

EV to Capital Employed

7.00

EV to Sales

3.83

PEG Ratio

1.65

Dividend Yield

0.02%

ROCE (Latest)

40.37%

ROE (Latest)

26.95%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 11.39% vs 0.42% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -7.69% vs -51.85% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.40",
          "val2": "23.70",
          "chgp": "11.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.60",
          "val2": "4.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.40",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.40",
          "val2": "2.60",
          "chgp": "-7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.10%",
          "val2": "163.30%",
          "chgp": "-1.82%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.27% vs 21.16% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 29.69% vs -14.67% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "115.50",
          "val2": "100.20",
          "chgp": "15.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "30.20",
          "val2": "24.90",
          "chgp": "21.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "1.20",
          "chgp": "41.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.40",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.60",
          "val2": "12.80",
          "chgp": "29.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "232.90%",
          "val2": "223.90%",
          "chgp": "0.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

26.40

23.70

11.39%

Operating Profit (PBDIT) excl Other Income

4.60

Interest

0.30

0.40

-25.00%

Exceptional Items

0.20

Consolidate Net Profit

2.40

2.60

-7.69%

Operating Profit Margin (Excl OI)

145.10%

163.30%

-1.82%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 11.39% vs 0.42% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -7.69% vs -51.85% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

115.50

100.20

15.27%

Operating Profit (PBDIT) excl Other Income

30.20

24.90

21.29%

Interest

1.70

1.20

41.67%

Exceptional Items

0.30

0.40

-25.00%

Consolidate Net Profit

16.60

12.80

29.69%

Operating Profit Margin (Excl OI)

232.90%

223.90%

0.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 15.27% vs 21.16% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 29.69% vs -14.67% in Dec 2023

All Annual Results

Company CV

About Pharmanutra SpA

Pharmanutra SpA

Pharmaceuticals & Biotechnology

Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Company Coordinates

Company Details

Via delle Lenze n. 216/B , PISA None : 56122

Tel:

http://www.pharmanutra.it/it/

Registrar Details